Results 81 to 90 of about 106,545 (283)

Paraneoplastic hypoglycaemia secondary to IGF-2 secretion from a metastatic gastrointestinal stromal tumour [PDF]

, 2020
We report the case of a 79-year-old male with previous history of non-Hodgkin's lymphoma in remission, who presented acutely to the Accident and Emergency department with recurrent episodes of hypoglycaemia.
Dimitriadis, Georgios K., Drakou, Eftychia E., Ganguly, Ratnadeep, Giovos, Georgios, Grossman, Ashley B., Kosmas, Christos, Leca, Bianca, Murthy, Narasimha, Onyema, Michael C., Randeva, Harpal S.   +9 more
core   +1 more source

Mechanochemical Strategies Applied to the Late‐Stage Modifications of Pharmaceutically Active Compounds

Angewandte Chemie International Edition, Accepted Article.
This review explores the potential of mechanochemistry in the late‐stage modification of active pharmaceutical ingredients (APIs), offering a comprehensive analysis of methods designed to transform structurally complex molecular scaffolds. By examining the scope, efficiency, and mechanistic aspects of these approaches, the review highlights protocols ...
Johanna Templ, Lars Borchardt
wiley   +1 more source

A Study of the Identification, Fragmentation Mode and Metabolic Pathways of Imatinib in Rats Using UHPLC-Q-TOF-MS/MS

Journal of Analytical Methods in Chemistry, 2021
In this study, The metabolites, metabolic pathways, and metabolic fragmentation mode of a tyrosine kinase inhibitor- (TKI-) imatinib in rats were investigated.
Sijiang Liu, Zhaojin Yu
doaj   +1 more source

Uptake of synthetic low density lipoprotein by leukemic stem cells — a potential stem cell targeted drug delivery strategy [PDF]

, 2010
Chronic Myeloid Leukemia (CML) stem/progenitor cells, which over-express Bcr-Abl, respond to imatinib by a reversible block in proliferation without significant apoptosis.
Alison M. Michie, Baillie, Bellodi, Bhatia, Bocchia, Brown, Claire Crossan, Collins, Copland, Davies, Deckelbaum, Dirks, Firestone, Gal, Gavin W. Halbert, Ghalaut, Graham, Halbert, Hamilton, Hamilton, Hatziieremia, Hayavi, Hayavi, Heather G. Jørgensen, Ho, Hochhaus, Holyoake, Hughes, Jordanides, Jorgensen, Jorgensen, Kramer, Linda Scobie, Moira A. Elliott, Nikanjam, Nikanjam, Owens, Peixun Zhou, Rousselot, Sophia Hatziieremia, Stingl, Tatidis, Tessa L. Holyoake, Vitols, Weisberg, White, White, WilsonRawls   +47 more
core   +1 more source

Non-Hodgkin's lymphoma in a chronic myelocytic leukemia patient treated with imatinib

Turkish Journal of Hematology, 2011
Imatinib is an important example of tyrosine kinase inhibitors (TKIs) used in clinical practice. Imatinib blocks the ATP binding site of the Bcr-Abl fusion protein and selectively inhibits Bcr-Abl tyrosine kinase (TK) activity.
Semra Paydaş, Berna Bozkurt Duman, Melek Ergin   +2 more
doaj   +3 more sources

Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2. [PDF]

, 2016
CML is effectively treated with tyrosine kinase inhibitors (TKIs). However, the efficacy of these drugs is confined to the chronic phase of the disease and development of resistance to TKIs remains a pressing issue.
Calabretta, Bruno, Canonico, Pier Luigi, Condorelli, Fabrizio, De Dominici, Marco, Genazzani, Armando A, Gnemmi, Ilaria, Mariani, Samanta A., Minassi, Alberto, Minieri, Valentina, Riva, Beatrice, Salomoni, Paolo   +10 more
core   +2 more sources

Erratum to: Exploiting the promiscuity of imatinib [PDF]

BMC Biology, 2010
An error in the PDB code occurred in the article published in the Journal of Biology [1]. In the legend to Figure One, instead of 1FW3, the correct PDB code is 3FW1.
Lee, Shun J, Wang, Jean YJ
openaire   +5 more sources

Exploring the Association Between Intra‐Patient Variability in Trough Concentration of Pazopanib and Clinical Outcomes in Renal Cell Carcinoma and Soft Tissue Sarcoma Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Pazopanib is an oral tyrosine kinase inhibitor used in patients with either metastatic renal cell carcinoma or soft tissue sarcoma. Pazopanib has a high interindividual variability in pharmacokinetics and pharmacodynamics and a well‐established exposure–response relationship. Therefore, therapeutic drug monitoring is recommended to improve the efficacy–
Amy Rieborn, Eline L. Giraud, Teun van Gelder, Hans Gelderblom, Nielka P. van Erp, Tom van der Hulle, Dirk Jan A. R. Moes   +6 more
wiley   +1 more source

BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein [PDF]

, 2013
Patients with chronic myeloid leukemia in whom tyrosine kinase inhibitors (TKIs) fail often present mutations in the BCR-ABL catalytic domain. We noticed a lack of substitutions involving 4 amino acids (E286, M318, I360, and D381) that form hydrogen ...
Alessandro Pandini, Chiara Romano, Deininger M., Elena Tirrò, Franca Fraternali, Francesco Di Raimondo, Livia Manzella, Michele Massimino, Nagar B., Paolo G. Vigneri, Pietro Buffa, Shah N. P.   +11 more
core   +1 more source

Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?

ESC Heart Failure, Volume 12, Issue 2, Page 1447-1454, April 2025.
This study analyzes 148 patients (66 women and 82 men) with chronic myeloid leukemia treated with tyrosine kinase inhibitors, focusing on cardiovascular adverse events. The risk assessment, performed using the HFA/ICOS score, reveals sex‐specific differences: venous thrombosis is more common in women, while arterial thrombosis predominates in men.
Cristina Madaudo, Daniela Di Lisi, Antonio Cannatà, Federica Manfrè, Celeste Vullo, Marco Santoro, Ciro Botta, Salvatrice Mancuso, Sergio Siragusa, Alfredo Ruggero Galassi, Giuseppina Novo   +10 more
wiley   +1 more source